For the Inventor, By the Inventor

Enter assignee name

Stamford, CT, United States of America

Purdue Pharmaceutical Products L.p.

USPTO Granted Patents = 24

% Expired Patents = 4.2

Trademarks = 2

Forward Citations = 280

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

Thomas Jorg Mehrling (13 out of 25 patents)

Enrique Maria Ocio (7 out of 8 patents)

Yi Heng Chen (5 out of 77 patents)

4. Yu Cheng Chen (5 out of 60 patents)

5. James C Chen (4 out of 50 patents)

6. Rosaria De Filippi (3 out of 3 patents)

7. Antonio Pinto (3 out of 3 patents)

8. David B Shine (3 out of 18 patents)

9. Claudio Festuccia (2 out of 3 patents)

10. Jonathan S Dahm (2 out of 16 patents)

11. William Louis Barnard (2 out of 16 patents)

12. Hugh Narciso (1 out of 10 patents)

13. Lars Hermann (1 out of 2 patents)

14. Phillip Burwell (1 out of 5 patents)

15. Zihong Guo (1 out of 22 patents)

24 patents: Sort by Forward Citations

1. 12440475 - Hodgkin lymphoma therapy (2025-10-14),

2. 12403130 - Pharmaceutical combinations for treating cancer (2025-09-02),

3. 12370177 - Compounds for treating brain cancer (2025-07-29),

4. 12064417 - Combination comprising a glucocorticoid and EDO-S101 (2024-08-20),

5. 12048688 - Pharmaceutical combinations for treating cancer (2024-07-30),

6. 11766424 - Hodgkin lymphoma therapy (2023-09-26),

7. 11559516 - Pharmaceutical combinations for treating cancer (2023-01-24),

8. 11541038 - Combination comprising a glucocorticoid and EDO-S101 (2023-01-03),

9. 11419853 - Compounds for treating brain cancer (2022-08-23),

10. 11266631 - Hodgkin lymphoma therapy (2022-03-08),

11. 10744120 - Combination comprising a glucocorticoid and EDO-S101 (2020-08-18),

12. 10507205 - Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts (2019-12-17),

13. 10406138 - Pharmaceutical combinations for treating cancer (2019-09-10),

14. 10118901 - Therapeutic agents (2018-11-06),

15. 9993482 - Pharmaceutical combination comprising a class III receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule EDO-S101 together with its use in the treatment of cancer (2018-06-12),

Company Overview

Purdue Pharmaceutical Products L.P., headquartered in Stamford, CT, specializes in the development and manufacturing of innovative pharmaceutical products. The company focuses on addressing unmet medical needs through advanced drug delivery systems and formulations. With a commitment to research and development, Purdue aims to enhance patient care by providing effective therapies, particularly in pain management and addiction treatment. Its expertise lies in creating solutions that prioritize safety and efficacy, contributing to the broader healthcare landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

24 Patents

#39 in Stamford, CT

#341 in Connecticut

#13,884 in US

#26,660 in the World

Stamford, CT, United States of America

Purdue Pharmaceutical Products L.p.

Forward Citations = 280

23 inventors:

Thomas Jorg Mehrling (13 out of 25 patents)

Enrique Maria Ocio (7 out of 8 patents)

Yi Heng Chen (5 out of 77 patents)

4. Yu Cheng Chen (5 out of 60 patents)

5. James C Chen (4 out of 50 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Purdue Pharmaceutical Products L.p.. Retrieved from https://idiyas.com/company/purdue-pharmaceutical-products

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…